What type of disease is giritinib used to treat?

Gilitinib is an oral, small molecule tyrosine kinase inhibitor mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3 mutations. FLT3 is a common form of gene mutation. About 30% of AML patients carry this mutation. This mutation is associated with rapid disease progression and poor prognosis. Giritinib specifically targets FLT3 mutations for precise inhibition, providing a new treatment option for such high-risk patients.

The drug is mainly used for relapsed or refractory FLT3 mutation-positive AML patients, especially those who still relapse after conventional chemotherapy or bone marrow transplantation. Traditional treatments have limited efficacy for these patients, and the emergence of giritinib fills this treatment gap. In relevant clinical studies, giritinib significantly prolonged the overall survival of patients and improved the complete remission rate. It is one of the standard treatment options currently recommended by international guidelines.

The mechanism of action of giritinib is mainly to inhibit the tyrosine kinase activity of FLT3 protein, thereby blocking the signaling pathway of cancer cell proliferation. In addition, it can also inhibit a variety of other kinases related to the growth of leukemia cells, such as AXL, ALK, etc., so it has a wide range of anti-tumor activities. This multi-target mechanism of action gives it significant advantages in the treatment of relapsed or drug-resistant AML.

In short, giritinib is a targeted therapy drug specifically targeting FLT3 mutated acute myeloid leukemia, and is suitable for patients with relapsed or refractory AML. The drug precisely controls the disease by targeting molecular mechanisms, bringing hope to patients to extend their survival and improve their quality of life. During use, patients need to closely cooperate with doctors to monitor blood images, liver function and other indicators to ensure medication safety and maximize therapeutic effects.

Reference materials:https://www.xospata.com/